Adalimumab induces deep remission in patients with Crohn's disease

Clicks: 388
ID: 268728
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #8 of 38 articles by views in clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In an exploratory study of patients with moderate to severe ileocolonic CD who received adalimumab induction and maintenance therapy, patients achieving deep remission appeared to have better 1-year outcomes than those not achieving deep remission. These findings should be validated in large, prospe …
Reference Key
jf2014clinicaladalimumab Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Colombel JF;Rutgeerts PJ;Sandborn WJ;Yang M;Camez A;Pollack PF;Thakkar RB;Robinson AM;Chen N;Mulani PM;Chao J;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2014
DOI
DOI not found
URL
https://www.pubmed.gov/23856361/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged Remission Induction Randomized Controlled Trial Antibodies Monoclonal Humanized / therapeutic use* anti-inflammatory agents / therapeutic use* crohn disease / drug therapy* placebos / administration & dosage jean-frédéric colombel adalimumab crohn disease / pathology pmid:23856361 doi:10.1016/j.cgh.2013.06.019 paul j rutgeerts jingdong chao

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.